Overview of Bison
| Property | Description |
|---|---|
| Active ingredient | Sildenafil (Sildenafil citrate) |
| Form | Oral tablet |
| Pharmacological class | Phosphodiesterase type 5 (PDE5) inhibitor |
| General purpose | Enhancing localized blood flow |
| Origin | Synthetic organic compound |
Defining Bison: A Selective PDE5 Inhibitor
Bison is a proprietary, single-ingredient pharmaceutical preparation containing Sildenafil (specifically Sildenafil citrate). The medication is formally classified as a Phosphodiesterase type 5 (PDE5) inhibitor. This classification indicates that its mechanism relies on selectively blocking the action of the PDE5 enzyme, a key molecular regulator found in the smooth muscle tissue of certain blood vessels. The preparation is formulated as an oral tablet, indicating its established route for systemic absorption and distribution throughout the body. As a prescription-only medicine (Rx), Bison is positioned to meet the specific requirements of adult patient populations requiring vascular support.
What Is the Composition and Origin of Sildenafil?
The foundational element of this medication is the Sildenafil chemical compound, which is a synthetic organic compound derived through precise chemical processes, ensuring consistency and purity. Bison is a single-ingredient product, containing only Sildenafil as the medicinal substance. The oral tablet is manufactured using the active Sildenafil along with various inert pharmaceutical excipients—non-active materials—which are necessary to stabilize the drug and facilitate its correct breakdown and absorption in the gastrointestinal tract. This synthetic origin allows for a standardized product suitable for reliable oral administration.
General Purpose: Enhancing Localized Blood Flow
The general purpose of Bison is to support and improve localized blood perfusion by increasing the functional capacity of specific blood vessels. This effect is achieved because the medication inhibits the PDE5 enzyme, thereby enhancing the action of the body's natural signaling molecule, nitric oxide (NO). This potentiation leads to the relaxation of smooth muscle within arterial walls, a process known as vasodilation. This fundamental action, which is clinically recognized for improving vascular response, subsequently allows for increased blood flow capacity to targeted tissues, serving the general goal of managing conditions limited by insufficient vascular supply.
Regulatory References

